Disease stratification in GCA and PMR: state of the art and future perspectives

[1]  E. Matteson,et al.  Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica , 2023, Annals of the rheumatic diseases.

[2]  A. Tomelleri,et al.  Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study. , 2023, Seminars in arthritis and rheumatism.

[3]  A. Tomelleri,et al.  Positron Emission Tomography Imaging in Vasculitis. , 2023, Cardiology clinics.

[4]  M. Akiyama,et al.  Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy , 2022, Rheumatology International.

[5]  P. Hilliquin,et al.  Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. , 2022, JAMA.

[6]  A. Diepstra,et al.  Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica , 2022, Annals of the Rheumatic Diseases.

[7]  T. Kwee,et al.  Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica , 2022, Frontiers in Immunology.

[8]  P. Heeringa,et al.  OP0015 PROINFLAMMATORY MONOCYTES AND MACROPHAGES IN SYNOVIAL FLUID AND BURSAL TISSUE OF PATIENTS WITH POLYMYALGIA RHEUMATICA: POTENT PRODUCERS OF IL-6 AND GM-CSF , 2022, Annals of the Rheumatic Diseases.

[9]  L. Hemkens,et al.  Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. , 2022, Seminars in arthritis and rheumatism.

[10]  G. Krönke,et al.  Synovial Macrophage and Fibroblast Heterogeneity in Joint Homeostasis and Inflammation , 2022, Frontiers in Medicine.

[11]  D. Sinha,et al.  Efficacy of leflunomide as a steroid‐sparing agent in treatment of Indian giant cell arteritis patients: A 2‐year follow‐up study , 2022, International journal of rheumatic diseases.

[12]  I. Wicks,et al.  Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2022, Annals of the Rheumatic Diseases.

[13]  P. Heeringa,et al.  Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica , 2022, Arthritis Research & Therapy.

[14]  P. Mandl,et al.  Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial , 2022, Annals of the Rheumatic Diseases.

[15]  K. Bondensgaard,et al.  Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis , 2022, Annals of the Rheumatic Diseases.

[16]  E. Matteson,et al.  Looking ahead: giant-cell arteritis in 10 years time , 2022, Therapeutic advances in musculoskeletal disease.

[17]  J. Burns,et al.  Global epidemiology of vasculitis , 2021, Nature Reviews Rheumatology.

[18]  S. Mackie,et al.  A shared basis for overlapping immunopathologies in giant cell arteritis and polymyalgia rheumatica , 2021, The Lancet Rheumatology.

[19]  A. Diamantopoulos,et al.  The fast-track outpatient clinic significantly decreases hospitalisation rates among polymyalgia rheumatica patients , 2021, BMC Rheumatology.

[20]  A. Tomelleri,et al.  Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage , 2021, The Lancet Rheumatology.

[21]  H. Küçük,et al.  Diagnostic utility of serum biomarkers in large vessel vasculitis and their correlation with positron emission tomography. , 2021, Modern rheumatology.

[22]  F. V. D. van den Hoogen,et al.  Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial , 2021, The Lancet Rheumatology.

[23]  Ashwini Kini,et al.  The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis , 2021, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[24]  W. Schmidt,et al.  Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial , 2021, Trials.

[25]  G. Schett,et al.  Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases , 2021, Nature Reviews Rheumatology.

[26]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis care & research.

[27]  R. Slart,et al.  Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica , 2021, Rheumatology.

[28]  P. Heeringa,et al.  A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis , 2021, Arthritis & rheumatology.

[29]  Patrik L. Ståhl,et al.  Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis , 2021, Annals of the Rheumatic Diseases.

[30]  A. Tomelleri,et al.  Current and innovative therapeutic strategies for the treatment of giant cell arteritis , 2021 .

[31]  J. Stone,et al.  Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial , 2021 .

[32]  S. Hayreh.  Giant cell arteritis: Its ophthalmic manifestations , 2021, Indian journal of ophthalmology.

[33]  J. Maillefert,et al.  The frequency of occult solid malignancy in patients with polymyalgia rheumatica-like symptoms , 2021, Therapeutic advances in musculoskeletal disease.

[34]  F. Jamar,et al.  Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  A. Tomelleri,et al.  Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss , 2020, Rheumatology.

[36]  G. Fragoulis,et al.  Correspondence on ‘Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia’ , 2020, Annals of the Rheumatic Diseases.

[37]  J. Pope,et al.  A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.

[38]  C. Dejaco,et al.  New insights into the role of imaging in polymyalgia rheumatica. , 2020, Rheumatology.

[39]  A. Tomelleri,et al.  Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. , 2020, RMD open.

[40]  C. Prati,et al.  Prognostic Value of 18F-Fluorodeoxyglucose PET-CT score at baseline on the therapeutic response to prednisone in patients with polymyalgia rheumatica. , 2020, Joint bone spine.

[41]  A. Scott,et al.  Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica , 2020, International journal of rheumatic diseases.

[42]  P. Heeringa,et al.  Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis , 2020, Clinical & translational immunology.

[43]  E. Matteson,et al.  Polymyalgia Rheumatica and Giant Cell Arteritis. , 2020, JAMA.

[44]  J. Jackson,et al.  Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA) , 2020, BMC Rheumatology.

[45]  S. Mackie,et al.  Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis , 2020, JAMA internal medicine.

[46]  C. Turesson,et al.  Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. , 2020, Seminars in arthritis and rheumatism.

[47]  K. Amano,et al.  Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. , 2020, Rheumatology.

[48]  C. Crowson,et al.  Giant cell arteritis and its mimics: A comparison of three patient cohorts. , 2020, Seminars in arthritis and rheumatism.

[49]  T. Horita,et al.  Gadolinium-enhanced magnetic resonance imaging in shoulders contributes accurate diagnosis and predicting recurrence to patients with polymyalgia rheumatica. , 2020, Clinical and experimental rheumatology.

[50]  C. Fraser,et al.  Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis , 2020, International journal of rheumatic diseases.

[51]  K. Akashi,et al.  Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica , 2020, Rheumatology International.

[52]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[53]  M. Isobe,et al.  Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions , 2020, Arthritis Research & Therapy.

[54]  R. Luqmani,et al.  Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia , 2020, Annals of the rheumatic diseases.

[55]  F. Orsini,et al.  Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis , 2019, Clinical Rheumatology.

[56]  F. Buttgereit,et al.  Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis , 2019, RMD Open.

[57]  A. Aouba,et al.  Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. , 2019, Journal of autoimmunity.

[58]  P. Merkel,et al.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis , 2019, The Journal of Rheumatology.

[59]  A. Boots,et al.  Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica , 2019, Front. Immunol..

[60]  A. Boots,et al.  High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. , 2019, Rheumatology.

[61]  C. Turesson,et al.  2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.

[62]  A. Versari,et al.  Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. , 2019, Seminars in arthritis and rheumatism.

[63]  Courtney A. Roberts,et al.  Economic and objective burden of caregiving on informal caregivers of patients with systemic vasculitis. , 2019, Musculoskeletal care.

[64]  A. Saraux,et al.  Localized Myofascial Inflammation Revealed by Magnetic Resonance Imaging in Recent-onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy , 2019, The Journal of Rheumatology.

[65]  A. Boots,et al.  Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis , 2019, Rheumatology.

[66]  M. González-Gay,et al.  Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. , 2019, Seminars in arthritis and rheumatism.

[67]  M. Recher,et al.  Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses , 2019, Annals of the rheumatic diseases.

[68]  B. Griffiths,et al.  Giant cell arteritis: new concepts, treatments and the unmet need that remains. , 2018, Rheumatology.

[69]  K. Goffin,et al.  Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica—A prospective study of 99 patients , 2018, Rheumatology.

[70]  B. Dasgupta,et al.  Current and emerging therapies in large-vessel vasculitis. , 2018, Rheumatology.

[71]  G. Thallinger,et al.  Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patients , 2018, Clinical Rheumatology.

[72]  M. Tomšič,et al.  Does leflunomide have a role in giant cell arteritis? An open-label study , 2018, Clinical Rheumatology.

[73]  C. Kallenberg,et al.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018, Arthritis & rheumatology.

[74]  D. Bluemke,et al.  F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis , 2018 .

[75]  B. Bonnotte,et al.  Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. , 2018, Autoimmunity reviews.

[76]  Eric L Matteson,et al.  Large-vessel giant cell arteritis: diagnosis, monitoring and management , 2018, Rheumatology.

[77]  A. Scott,et al.  Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica , 2018, Rheumatology.

[78]  W. Schmidt.  Ultrasound in the diagnosis and management of giant cell arteritis , 2018, Rheumatology.

[79]  J. Rizzo,et al.  Ophthalmic manifestations of giant cell arteritis. , 2018, Rheumatology.

[80]  A. Saraux,et al.  Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab , 2018, Arthritis Research & Therapy.

[81]  A. Iagnocco,et al.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.

[82]  M. Alba,et al.  Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients , 2017, RMD Open.

[83]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[84]  J. Stone,et al.  Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[85]  J. Krischer,et al.  A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.

[86]  B. Bonnotte,et al.  Giant Cell Arteritis–related Stroke: A Retrospective Multicenter Case-control Study , 2017, The Journal of Rheumatology.

[87]  L. Cimino,et al.  Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. , 2017, Journal of autoimmunity.

[88]  G. Ferraccioli,et al.  Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study , 2017, The Journal of Rheumatology.

[89]  Z. Bortlíček,et al.  PET/CT imaging in polymyalgia rheumatica: praepubic 18F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis , 2017, Radiology and oncology.

[90]  M. Broder,et al.  Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. , 2016, Seminars in arthritis and rheumatism.

[91]  E. Matteson,et al.  The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.

[92]  B. Bonnotte,et al.  Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. , 2016, Journal of autoimmunity.

[93]  D. Huglo,et al.  F-fluorodeoxyglucose positron emission of subsequent aortic complications in giant-cell arteritis , 2016 .

[94]  J. Serfaty,et al.  Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. , 2016, Autoimmunity reviews.

[95]  M. Tomšič,et al.  Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis , 2016, Medicine.

[96]  H. Marques,et al.  Acute upper limb ischemia, a rare presentation of giant cell arteritis. , 2016, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[97]  R. Pathak,et al.  RS3PE revisited: a systematic review and meta-analysis of 331 cases. , 2016, Clinical and experimental rheumatology.

[98]  E. Matteson,et al.  Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. , 2016, Rheumatic diseases clinics of North America.

[99]  P. Emery,et al.  Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids , 2015, Annals of the rheumatic diseases.

[100]  K. Barraclough,et al.  2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2015, Annals of the rheumatic diseases.

[101]  R. Quirce,et al.  (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. , 2015, Revista espanola de medicina nuclear e imagen molecular.

[102]  A. Boots,et al.  Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. , 2015, Rheumatology.

[103]  Stephen G. Martin,et al.  Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation , 2015, Arthritis Research & Therapy.

[104]  U. Hoffmann,et al.  Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. , 2015, Journal of vascular surgery.

[105]  P. Gregersen,et al.  A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. , 2015, American journal of human genetics.

[106]  E. Matteson,et al.  Large-vessel giant cell arteritis: a cohort study. , 2015, Rheumatology.

[107]  H. Petri,et al.  Incidence of Giant Cell Arteritis and Characteristics of Patients: Data‐Driven Analysis of Comorbidities , 2015, Arthritis care & research.

[108]  B. Dasgupta,et al.  Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. , 2015, Clinical and experimental rheumatology.

[109]  A. Hewitt,et al.  Projected Worldwide Disease Burden from Giant Cell Arteritis by 2050 , 2015, The Journal of Rheumatology.

[110]  M. Alba,et al.  Relapses in Patients With Giant Cell Arteritis , 2014, Medicine.

[111]  P. Merkel,et al.  Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden , 2014, Annals of the rheumatic diseases.

[112]  M. Perretti,et al.  Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression , 2014, Circulation research.

[113]  B. Sheehan,et al.  A 12-month follow-up study of people with dementia referred to general hospital liaison psychiatry services. , 2013, Age and ageing.

[114]  F. Paparo,et al.  High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. , 2013, Rheumatology.

[115]  J. Moghimi,et al.  Efficacy of methotrexate in patients with polymyalgia rheumatica , 2013 .

[116]  W. Stone,et al.  Inflammatory aneurysms treated with EVAR. , 2012, Seminars in vascular surgery.

[117]  B. Bonnotte,et al.  Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. , 2012, Arthritis and rheumatism.

[118]  Mahboob Rahman,et al.  Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis , 2012, Annals of the rheumatic diseases.

[119]  B. Dasgupta,et al.  Efficacy and tolerability of leflunomide in difficult‐to‐treat polymyalgia rheumatica and giant cell arteritis: a case series , 2012, International journal of clinical practice.

[120]  D. Klatzmann,et al.  Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. , 2012, Arthritis and rheumatism.

[121]  A. Iagnocco,et al.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.

[122]  G. Deshpande,et al.  Clinical Characteristics of Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema Compared to Patients with Pure Polymyalgia Rheumatica , 2012, The Journal of Rheumatology.

[123]  L. Crofford,et al.  Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. , 2011, Clinical therapeutics.

[124]  E. Matteson,et al.  Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly , 2011 .

[125]  M. González-Gay,et al.  Relapses and Recurrences in Giant Cell Arteritis: A Population-Based Study of Patients With Biopsy-Proven Disease From Northwestern Spain , 2011, Medicine.

[126]  G. Garlaschi,et al.  Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: a magnetic resonance imaging study. , 2011, Rheumatology.

[127]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[128]  R. Olshen,et al.  Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.

[129]  C. Salvarani,et al.  Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. , 2009, Rheumatology.

[130]  M. González-Gay,et al.  Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis , 2009, Medicine.

[131]  A. Cerulli,et al.  The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. , 2009, Respiratory medicine.

[132]  Jiusheng Deng,et al.  Toll-Like Receptors 4 and 5 Induce Distinct Types of Vasculitis , 2009, Circulation research.

[133]  C. Leonardi,et al.  Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: Preliminary results of an open randomized study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[134]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[135]  W. Thomson,et al.  Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. , 2008, Rheumatology.

[136]  Olga Pryshchep,et al.  Vessel-Specific Toll-Like Receptor Profiles in Human Medium and Large Arteries , 2008, Circulation.

[137]  M. Langer,et al.  Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. , 2008, Arthritis and rheumatism.

[138]  M. Sonnenblick,et al.  Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. , 2008, Clinical and experimental rheumatology.

[139]  I. Olivieri,et al.  Cervical interspinous bursitis in active polymyalgia rheumatica , 2008, Annals of the rheumatic diseases.

[140]  A. Hutchings,et al.  Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? , 2007, Rheumatology.

[141]  A. Radjenovic,et al.  Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[142]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[143]  A. Cipriani,et al.  What is an individual patient data meta-analysis? , 2007, Epidemiologia e Psichiatria Sociale.

[144]  K. Chakravarty,et al.  Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. , 2007, Arthritis and rheumatism.

[145]  Mark Stevenson,et al.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. , 2007, Health technology assessment.

[146]  H. Kleinman,et al.  Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. , 2006, Rheumatology.

[147]  G. Hunder.  The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. , 2006, Mayo Clinic proceedings.

[148]  L. Mortelmans,et al.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.

[149]  L. Mortelmans,et al.  Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. , 2005, Rheumatology.

[150]  D. Consonni,et al.  Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. , 2005, Arthritis and rheumatism.

[151]  M. Vinceti,et al.  Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. , 2005, Arthritis and rheumatism.

[152]  R. Caporali,et al.  Prednisone plus Methotrexate for Polymyalgia Rheumatica , 2004, Annals of Internal Medicine.

[153]  T. Tedder,et al.  Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis , 2004, The Journal of experimental medicine.

[154]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[155]  W. Ollier,et al.  Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. , 2003, Seminars in arthritis and rheumatism.

[156]  F. Strutz,et al.  Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[157]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[158]  J. Fernandez-Solà,et al.  A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. , 2002, Arthritis and rheumatism.

[159]  R. Caporali,et al.  Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study , 2001, Annals of the rheumatic diseases.

[160]  M. Peterson,et al.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.

[161]  G. Gran.  Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis - A prospective two-year study in 273 patients , 2001, Scandinavian journal of rheumatology.

[162]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[163]  I. Olivieri,et al.  Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. , 2000, Seminars in arthritis and rheumatism.

[164]  I. Olivieri,et al.  Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. , 1998, Arthritis and rheumatism.

[165]  C. Salvarani,et al.  Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. , 1996, Arthritis and rheumatism.

[166]  G. A. van Albada-Kuipers,et al.  Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? , 1996, Annals of the rheumatic diseases.

[167]  F. Salaffi,et al.  Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. , 1996, The Journal of rheumatology.

[168]  G. Hunder,et al.  HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[169]  G. Panayi,et al.  Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. , 1990, British journal of rheumatology.

[170]  L. A. Healey,et al.  Polymyalgia rheumatica and giant cell arteritis. , 1984, The Western journal of medicine.

[171]  高井 俊夫.  奇形・脳性麻痺の起因に関するprospective follow up studyについて , 1966 .

[172]  T. Landberg,et al.  INVOLVEMENT OF LARGE VESSELS IN POLYMYALGIA ARTERITICA. , 1965, Lancet.

[173]  OUP accepted manuscript , 2021, Rheumatology.

[174]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[175]  P. Heeringa,et al.  What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018 .

[176]  G. Haugeberg,et al.  The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? , 2016, Rheumatology.

[177]  N. Arden,et al.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.

[178]  Javier Martín,et al.  Genetic component of giant cell arteritis. , 2014, Rheumatology.

[179]  J. Manson,et al.  Prospective Study of , 2007 .

[180]  R. Caporali,et al.  Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. , 2004, Annals of internal medicine.

[181]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[182]  Teresa Foo,et al.  : SYSTEMATIC LITERATURE REVIEW , 2004 .

[183]  P. Toutouzas,et al.  A Magnetic Resonance Imaging Study , 2003 .

[184]  E. Gromnica-ihle,et al.  Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. , 2002, Rheumatology.

[185]  J. Noval Menéndez,et al.  [Distal musculo-skeletal manifestations in rheumatic polymyalgia]. , 2002, Revista clinica espanola.

[186]  A. Arnold.  Ischemic optic neuropathies. , 2001, Ophthalmology clinics of North America.

[187]  D. Bacal.  Re: Caldeira JAF: Stage I intraoperative adjustment of eye muscle surgery forexodeviations based on eye position during general anesthesia: a prospective study of 35 patients. , 1998, Binocular vision & strabismus quarterly.

[188]  A. de la Sierra,et al.  Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. , 1998, Arthritis and rheumatism.

[189]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.